Engineered Bacteria Effectively Target Tumors, Enabling Tumor Imaging Potential In MiceMain Category: Cancer / Oncology
Also Included In: Infectious Diseases / Bacteria / Viruses; Medical Devices / Diagnostics
Article Date: 26 Jan 2012 - 2:00 PST
Engineered Bacteria Effectively Target Tumors, Enabling Tumor Imaging Potential In Mice
|Patient / Public:|
Tumor-targeted bioluminescent bacteria have been shown for the first time to provide accurate 3D images of tumors in mice, further advancing the potential for targeted cancer drug delivery, according to a study published in the Jan. 25 issue of the online journal PLoS ONE.
The specially engineered probiotic bacteria, like those found in many yoghurts, were intravenously injected into mice with tumors, after which the researchers took full body bioluminescent images. The 3D images revealed information about the number and location of the bacteria, to the level of precisely revealing where within the tumour the bacteria were living, providing much more information on the interaction of bacteria and tumors than was previously available using similar two-dimensional imaging methods.
According to the authors, led by Mark Tangney of University College Cork in Ireland, "before now, researchers used luminescence to provide an approximation of where a test organism was within the body, and would then follow up with multiple further experiments using different techniques to try to find a precise location". This new research suggests that such bacteria can be engineered to contain diagnostic or therapeutic agents that would be produced specifically within the tumor for targeted treatment.
Visit our cancer / oncology section for the latest news on this subject.
Financial Disclosure: The authors wish to acknowledge support relevant to this manuscript from the European Commission Seventh Framework Programme (PIOF-GA-2009-255466) and the Irish Health Research Board (HRA_POR/2010/138). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interest Statement: AA, JM, J-BK, NZ and KF are employees of Caliper Life Sciences. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Public Library of Science
24 May. 2013. <http://www.medicalnewstoday.com/releases/240777.php>
Please note: If no author information is provided, the source is cited instead.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.